Rezultati pretraživanja
  1. prije 38 minuta

    Checkpoint inhibitor therapies do not work in about 70% of cancer patients, and even patients who do show an initial response, many suffer a return of the disease.

  2. prije 1 sat

    Since its discovery in 2004, LSD1 has been pursued as an attractive target for cancer treatment.

  3. stocks worth to look at are

  4. LSD1 is often highly expressed in advanced metastatic prostate cancer patients, a leading cause of cancer-related deaths with no established cures.

  5. 5. velj

    - Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference (Auto: )

  6. Data Supports Continued Study of Seclidemstat with Checkpoint Inhibitors

  7. 4. velj
  8. 4. velj

    sent Scott another text to say hello...

  9. 4. velj

    Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

  10. 2. velj

    The Creating Hope Act creates an incentive for companies to develop drugs for pediatric rare diseases: a pediatric priority review voucher. has Priority Review Designation which turns into a Voucher upon approval of Seclidemstat.

  11. 2. velj

    Salarius is an early stage biotech with the possibility of near-term inflection points.

  12. 31. sij

    another investment ... going verticall-up.at-the-open " stocks worth to look at are : ... ... 6:48 AM · Jan 29, 2020·",by realtime trading@3TriggersTrader

  13. 29. sij

    New 52-Week Lows 3.68%, 3.82%, 3.92%, 3.98%, 4.01%, 4.21%, 4.58%, 6.11%, 6.2%, 20.08%

  14. 29. sij

    New 6-Month Lows 4.01%, 4.15%, 4.21%, 4.58%, 4.86%, 5.26%, 5.3%, 6.11%, 6.2%, 20.08%

  15. 29. sij

    stocks worth to look at are :

  16. 28. sij

    Like any recipe, epigenomes can switch out ingredients without changing genetic codes. Epigenetic illness occurs when the epigenome operates incorrectly or is hijacked.

  17. 24. sij

    Salarius Abstract: Trials in progress: A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma

  18. 17. sij
  19. 13. sij

    Content Carnivores Supporting Clients at Biotech Showcase/JP Morgan Healthcare Conference Week

  20. 9. sij

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.